title: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.
authors.affiliation: Department of Haematology, Hospital Clinic, IDIBAPS, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bladé
authors.forename: D
authors.initials: D
authors.lastname: Samson
authors.forename: D
authors.initials: D
authors.lastname: Reece
authors.forename: J
authors.initials: J
authors.lastname: Apperley
authors.forename: B
authors.initials: B
authors.lastname: Björkstrand
authors.forename: G
authors.initials: G
authors.lastname: Gahrton
authors.forename: M
authors.initials: M
authors.lastname: Gertz
authors.forename: S
authors.initials: S
authors.lastname: Giralt
authors.forename: S
authors.initials: S
authors.lastname: Jagannath
authors.forename: D
authors.initials: D
authors.lastname: Vesole
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents